SU 9516
SU 9516 structure
|
Common Name | SU 9516 | ||
|---|---|---|---|---|
| CAS Number | 377090-84-1 | Molecular Weight | 241.245 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 601.5±55.0 °C at 760 mmHg | |
| Molecular Formula | C13H11N3O2 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 317.6±31.5 °C | |
|
The FGF-1-specific single-chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and metastasis.
J. Cell. Mol. Med. 18(10) , 2061-70, (2014) Immunotherapy mediated by recombinant antibodies is an effective therapeutic strategy for a variety of cancers. In a previous study, we demonstrated that the fibroblast growth factor 1 (FGF-1)-specific recombinant antibody scFv1C9 arrests the cell cycle at th... |
|
|
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Mol. Pharmacol. 70(2) , 645-55, (2006) Mechanisms of lethality of the three-substituted indolinone and putatively selective cyclin-dependent kinase (CDK)2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) were examined in human leukemia cells. Exposure ... |
|
|
You never know: Cdk inhibitors as anti-cancer drugs.
Cell Cycle 7(24) , 3789-90, (2008) Ever since it emerged that cyclin-dependent protein kinases catalyzed cell cycle transitions and with cancer seen as "a disease of the cell cycle," people have pursued the aim of testing kinase inhibitors as anti-cancer drugs. Quite early on, Laurent Meijer a... |